Search results
Showing 151 to 165 of 661 results for diabetes
Evidence-based recommendations on using coronary artery stents in adults.
Evidence-based recommendations on empagliflozin (Jardiance) for treating chronic kidney disease in adults.
This quality standard covers recognising, assessing and managing bipolar disorder in adults (aged 18 and over) in primary and secondary care. It describes high-quality care in priority areas for improvement.
View quality statements for QS95Show all sections
Sections for QS95
- Quality statements
- Quality statement 1: Referral for specialist mental health assessment
- Quality statement 2: Personalised care plan
- Quality statement 3: Involving carers in care planning
- Quality statement 4 (developmental): Psychological interventions
- Quality statement 5: Maintaining plasma lithium levels
- Quality statement 6: Valproate
- Quality statement 7: Assessing physical health
This guideline covers managing stable angina in people aged 18 and over. It outlines the importance of addressing the person’s concerns about stable angina and the roles of medical therapy and revascularisation.
Bipolar, schizophrenia and other psychoses: annual blood glucose or HbA1c (IND159)
This indicator covers the percentage of patients aged 18 years and over with schizophrenia, bipolar affective disorder and other psychoses who have a record of blood glucose or HbA1c in the preceding 12 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM130
Evidence-based recommendations on dapagliflozin for treating chronic kidney disease in adults.
This quality standard covers the assessment and management of chronic kidney disease in adults (aged 18 and over). It describes high-quality care in priority areas for improvement.
This quality standard covers preventing, detecting and managing acute kidney injury in adults, young people and children. It describes high-quality care in priority areas for improvement.
View quality statements for QS76Show all sections
Sections for QS76
- Quality statements
- Quality statement 1: Raising awareness in people at risk
- Quality statement 2: Identifying acute kidney injury in people admitted to hospital
- Quality statement 3: Response to acute kidney injury warning stage 2 test result
- Quality statement 4: Response to acute kidney injury warning stage 3 test result
- Quality statement 5: Referral for renal replacement therapy
- Quality statement 6: Clinical review after hospital discharge
- Update information
Cellulitis and erysipelas: antimicrobial prescribing (NG141)
This guideline sets out an antimicrobial prescribing strategy for adults, young people, children and babies aged 72 hours and over with cellulitis and erysipelas. It aims to optimise antibiotic use and reduce antibiotic resistance.
type 2 diabetes: What is the long-term effect of bariatric surgery on diabetes-related complications and quality of life in...
Adrenal insufficiency: identification and management (NG243)
This guideline covers identifying and managing adrenal insufficiency (hypoadrenalism) in babies, children, young people and adults. It aims to improve the treatment of primary, secondary and tertiary adrenal insufficiency, and the prevention and management of adrenal crisis.
Resmetirom for treating non-alcoholic steatohepatitis and liver fibrosis [ID6529]
In development Reference number: GID-TA11414 Expected publication date: 10 June 2026
Drug-eluting stents for the treatment of coronary artery disease (TA152)
Evidence-based recommendations on using drug-eluting stents in adults.
type 3c diabetes:- What is the most clinically effective and cost-effective insulin regimen to minimise hypo- and hyperglycaemia for...
Continuous glucose monitoring in children and young people with type 2 diabetes: What is the effectiveness and cost effectiveness of...